{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-022539","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.179060+00:00","generated_at":"2026-05-15T22:19:04.866334+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Passage Bio reports 2025 net loss of $45.5M; cash runway through Q1 2027; advances FTD clinical program","bullets":["Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.","Net loss of $45.5M ($14.35/diluted share) for 2025, improved from $64.8M ($21.04/sh) in 2024.","R&D expenses $23.3M in 2025, down from $40.2M in 2024; G&A $19.9M vs $25.0M.","Enrolled first 3 FTD-GRN patients in Cohort 3; dosed first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.","Expects interim safety/biomarker data and regulatory feedback on FTD-GRN registrational trial in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-022539","json":"https://secwatch.observer/filing/0001104659-26-022539.json","markdown":"https://secwatch.observer/filing/0001104659-26-022539.md","text":"https://secwatch.observer/filing/0001104659-26-022539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/0001104659-26-022539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/pasg-20260303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:19:04.866334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}